Novo Nordisk A/S (NYSE:NVO) Shares Sold by First Trust Advisors LP

First Trust Advisors LP trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,900 shares of the company’s stock after selling 338 shares during the period. First Trust Advisors LP’s holdings in Novo Nordisk A/S were worth $202,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Jane Street Group LLC raised its stake in Novo Nordisk A/S by 1,357.0% during the 2nd quarter. Jane Street Group LLC now owns 188,490 shares of the company’s stock valued at $9,620,000 after acquiring an additional 175,553 shares during the last quarter. Meritage Portfolio Management grew its stake in shares of Novo Nordisk A/S by 12.7% in the 3rd quarter. Meritage Portfolio Management now owns 52,893 shares of the company’s stock valued at $2,735,000 after purchasing an additional 5,954 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of Novo Nordisk A/S by 13.6% in the 3rd quarter. Quadrant Capital Group LLC now owns 19,750 shares of the company’s stock valued at $1,007,000 after purchasing an additional 2,372 shares during the last quarter. BB&T Corp increased its holdings in shares of Novo Nordisk A/S by 1.9% in the third quarter. BB&T Corp now owns 153,952 shares of the company’s stock valued at $7,960,000 after purchasing an additional 2,868 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Novo Nordisk A/S by 89.5% in the second quarter. Jennison Associates LLC now owns 1,229,986 shares of the company’s stock valued at $62,778,000 after purchasing an additional 580,944 shares during the period. Institutional investors and hedge funds own 7.32% of the company’s stock.

Novo Nordisk A/S stock opened at $56.74 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.00 and a quick ratio of 0.73. Novo Nordisk A/S has a 1-year low of $43.60 and a 1-year high of $58.01. The company has a market cap of $134.36 billion, a PE ratio of 22.52, a price-to-earnings-growth ratio of 2.26 and a beta of 0.61. The stock’s 50 day moving average price is $55.65 and its 200 day moving average price is $51.72.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Friday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. The firm had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.55 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 2.44 EPS for the current fiscal year.

Several brokerages recently weighed in on NVO. Barclays raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Wednesday, November 27th. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, November 18th. Finally, Jefferies Financial Group cut shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research note on Friday, August 30th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $159.65.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: What is basic economics?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.